NAS:PBYI (USA) Also Trade In: Germany
Puma Biotechnology Inc $ 9.11 0 (0%)
Warning! GuruFocus has detected 4 Severe warning signs with PBYI. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for PBYI (Puma Biotechnology Inc) from 2012 to Oct 29 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Puma Biotechnology stock (PBYI) PE ratio as of Oct 29 2020 is 0. More Details
Puma Biotechnology PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Puma Biotechnology PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:IMRA NAS:XENE NAS:DVAX NAS:BDSI NAS:SIGA NAS:ANIK NAS:BYSI NAS:VYGR NAS:SYRS NAS:PRTA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.